š§¬ PT-141 ā Melanocortin Receptor Agonist for Sexual Arousal & Neuroendocrine Research
Synonyms: Bremelanotide, Vyleesi, Ī±-MSH Analog
CAS Number: 189691-06-3
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular Weight: ~1025.2 Da
Form: Lyophilized powder or pre-filled auto-injector
Purity: ā„98% (HPLC)
Research Use Only. This compound is not approved for human or veterinary use..
---
Description:
PT-141 is a synthetic melanocortin receptor agonist derived from Melanotan II, designed to selectively activate MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors, PT-141 works centrally, bypassing vascular pathways and directly stimulating sexual desire and arousal via hypothalamic signaling. It is FDA-approved under the name Bremelanotide for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, and is under investigation for male erectile dysfunction, especially in sildenafil non-responders.
---
āļø Mechanism of Action:
PT-141 binds to melanocortin receptors in the CNS, particularly MC4R, triggering:
ā¢ Dopamine release in the medial preoptic area and hypothalamus
ā¢ Sexual arousal independent of visual or tactile stimulation
ā¢ Increased genital blood flow via neurogenic vasodilation
ā¢ Appetite suppression and mild mood elevation in some models
Its non-hormonal, non-vascular mechanism makes it a unique scaffold for studying neuroendocrine arousal pathways.
---
š Research Applications:
PT-141 is under investigation in preclinical and clinical models for:
ā¢ Female sexual dysfunction (HSDD, FSAD)
ā¢ Male erectile dysfunction (ED)
ā¢ Neuroendocrine signaling and dopamine modulation
ā¢ Appetite regulation and melanocortin pathway mapping
ā¢ Combination therapy with PDE5 inhibitors or amylin analogs
In clinical trials, PT-141 demonstrated statistically significant increases in sexual desire and satisfaction, with onset typically within 30ā60 minutes post-injection.
---
š§Ŗ Dosing & Handling (Preclinical):
ā¢ Typical dose: 1ā2 mg SubQ; up to 10 mg in ED models
ā¢ Onset: ~45 minutes; peak effect at 1ā2 hours
ā¢ Duration: ~6ā8 hours
ā¢ Cycle: No more than 8 doses/month (per FDA guidelines for HSDD)
ā¢ Reconstitution: Use bacteriostatic water;
ā¢ Store in the refrigerator once a reconstituted solution to preserve integrity 2-8Ā°C
---
š¦ Packaging & Storage:
Supplied as lyophilized powder or pre-filled auto-injector pens.
Reconstitute under sterile conditions. For research use only
